A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

NCT07701486 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreas Cancer, Metastatic
Pancreas Cancer, Stage IV
Ductal Adenocarcinoma of the Pancreas

Interventions

BIOLOGICAL: VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)
DRUG: Nab-paclitaxel + Gemcitabine

Sponsor

Theriva Biologics SL